-
Press ReleaseNovartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
-
Press ReleaseNovartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
-
Press ReleaseNovartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
-
Press ReleaseNovartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
-
Story
A scientist from the start – Q&A with NIBR President Fiona Marshall -
Story
In neuroscience, “an inflection point in knowledge and technology” -
Press ReleaseNovartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
-
Story
When it comes to cancer, there’s power in a good partner -
Story
Stopping this coronavirus – and the next one -
Story
Solving the puzzle of immunotherapy -
Press ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Press ReleaseNovartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)